Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Drug Review Regulation United States

Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT

  • Analysis

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

You may also be interested in...



Keeping Track: Furoscix, SPN-830 Show Difficulties Of Drug-Device Combinations

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission

The company announced interim results of the FREEDOM-HF study showing nearly $18,000 in savings per heart failure patient.

Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Table

View full table

Related Content

Scrip
Scrip
Pink Sheet
Pink Sheet
Scrip
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
Drug Review Regulation United States
Latest Headlines

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings

Recent And Upcoming FDA Advisory Committee Meetings

EU CHMP Opinions and MAA Updates

See All
UsernamePublicRestriction

Register

PS123312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By